Alzheimer Drugs Market
Alzheimer Drugs Market is segmented By Drugs Type (Donepezil, Galantamine, Rivastigmine, Memantine), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Sales), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Size, Share Outlook, and Opportunity Analysis, 2022-2029.
Alzheimer Drugs Market is expected to reach a CAGR 8% during the forecast period (2022-2029).
Alzheimer’s is the most common cause of dementia, a general term for memory loss and other cognitive abilities severe enough to interfere with daily life. Alzheimer’s disease accounts for 60 percent to 80 percent of dementia cases. The common symptoms of Alzheimer's include depression, memory impairment, loss of inhibitions, and problems with thinking and reasoning.
Alzheimer Drugs Market
|
Metrics |
Details |
|
Market CAGR |
8% |
|
Segments Covered |
By Drugs Type, By Distribution Channel, and By Region |
|
Report Insights Covered |
Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
|
Fastest Growing Region |
Asia Pacific |
|
Largest Market Share |
North America |
Alzheimer Drugs Market Dynamics
The growth of the global alzheimer drugs market is driven by the the increasing prevalence of chronic diseases like dementia, increasing pipeline drug development, investment in biomarkers for drug development, and increasing sophisticated diagnostics for early detection.
The extensive research studies being conducted related to alzheimer's disease will drive the market growth
The extensive research studies being conducted related to alzheimer's disease are further accelerating the market growth. For instance, in October 2020, ImmunoBrain Checkpoint Inc. was funded USD 1,000,000 by the Alzheimer’s Association to aid the Phase 1 clinical trial for "IBC-Ab002" in the treatment of Alzheimer's. This is expected to accelerate the market growth. Also, the National Institute of Health reported that in July 2019, there were 132 agents in clinical trials for AD; 28 agents were in 42 Phase 3 trials, 74 agents were in 83 Phase 2 trials, and 30 agents were in 31 Phase 1 trials. There was an increasing number of agents in each phase compared to the 2018 pipeline.
According to the World Alzheimer Report, in 2019, around 50 million people worldwide were reported to be suffering from Alzheimer's and related dementia, and this number is further expected to reach 152 million by 2050. The U.S. Food and Drug Administration (FDA) approved two types of medications, cholinesterase inhibitors (Aricept, Exelon, Razadyne) and memantine (Namenda) to treat the cognitive symptoms (memory loss, confusion, and problems with thinking and reasoning) of Alzheimer disease. Hence, the increasing number of clinical studies for diagnosis and treatment of alzheimer's is expected to drive the market growth.
Lack of well-defined standards of common data is likely to hamper the market growth
However, high prices of advanced drugs, failing of investigational candidate in late-stage, and awareness about alzheimer disease remains limited in developing countries might hamper the global alzheimer drugs market in the forecast period.
COVID-19 Impact Analysis
The study titled, "Alzheimer’s and Parkinson’s diseases predict different COVID-19 outcomes, a UK Biobank study", published in November 2020, exhibited that patients suffering from dementia are at the highest risk of mortality from COVID-19. During this pandemic situation, cholinesterase is being studied extensively for its safety, efficacy, and side effects in Alzheimer's patients with COVID-19 infection. As per the study titled, "Potential Novel Role of COVID-19 in Alzheimer’s Disease and Preventative Mitigation Strategies", published in June 2020, the cholinergic anti-inflammatory pathway was observed to be a viable target to control inflammation and for the prevention of cytokine storm post detection of COVID-19 virus infection in Alzheimer's patients, and acetylcholinesterase inhibitors can potentially be administered as an adjunctive therapy.
However, there have been many reports of neurologic complications associated with COVID-19. The COVID-19 pandemic has also caused drastic changes in Alzheimer's patients’ normal routine with social distancing and lockdowns in place in the United States. Understandably, many Alzheimer's patients have experienced a negative impact on their mental health.
Alzheimer Drugs Market Segment Analysis
Galantamine segment is expected to grow at the fastest CAGR during the forecast period (2021-2028)
Galantamine is in a class of medications called acetylcholinesterase inhibitors. It works by increasing the amount of a certain natural substance in the brain that is needed for memory and thought. Galantamine may improve the ability to think and remember or slow the loss of these abilities in people who have alzheimer's. Galantamine comes as a tablet, an extended-release (long-acting) capsule, and a solution (liquid) to take by mouth. Galantamine may upset stomach, especially at the beginning of treatment. Some of the drugs approved by the United States Food & Drug Administration are Aricept, Exelon, and Razadyne indicated against mild to moderate Alzheimer's. Furthermore, companies are investing in the development of new drugs. Apart from this, various Alzheimer's drugs are presently under late-stage clinical trials, including Aducanumab, Solanezumab and Insulin. The development of these drugs is anticipated to propel the market growth in the forecast period.
Alzheimer Drugs Market Geographical Analysis
North America region holds the largest market share of global alzheimer drugs market
North America accounts for the largest share in the global alzheimer drugs market in 2020 and is expected to remain dominant over the forecast period. The rising geriatric population is one of the key factors responsible for the market growth in this country, as the older population is at a higher risk of acquiring the disease. As per the United States Census Bureau data, in 2019, about 54 million Americans were aged 65 years and above. Furthermore, according to the Alzheimer’s Association, more than 5.8 million Americans suffer from Alzheimer’s disease, as of 2020. Hence, the rising geriatric population, coupled with the rising burden of the disease, is expected to boost the demand for alzheimer drugs market in this country.
The United States is considered to be the global leader in Alzheimer’s disease intervention and management. According to the Alzheimer's Association, the total healthcare expenditure on patients with dementia was estimated to be USD 357,297 in 2019. Furthermore, the increasing number of research studies related to the diagnosis and management of Alzheimer's disease is expected to drive the market growth in the region.
Alzheimer Drugs Market Competitive Landscape
The Alzheimer Drugs Market is moderately competitive presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include F. Hoffmann-La Roche, Novartis AG, Merck & Co., Pfizer Inc., Eli Lily and Co., Biogen Inc., Johnson & Johnson, Lupin Limited, Abbvie Inc (Allergan),Siemens Healthineers among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the Alzheimer Drugs Market globally. For instance, in August 2020, Biogen and Eisai Co. Ltd announced the approval of the Biologics License Application by the United States Food & Drug Administration (US FDA) for ''aducanumab'', which is being studied for the treatment of Alzheimer's disease.
Eli Lily and Co.
Overview:
Eli Lilly and Company is a drug manufacturing company. The Company is engaged in the discovery, development, manufacturing, marketing, and sales of pharmaceutical products across the world. The Company's diabetes products include Baqsimi, Basaglar, Humalog, Humulin, Jardiance, Lyumjev, Trajenta and Trulicity.
Product Portfolio:
Amyvid™ (Florbetapir F 18 Injection): Amyvid is a radioactive diagnostic agent that is injected into the bloodstream, where it crosses the blood-brain barrier and selectively binds to amyloid plaques. It is approved in European Union for Use in Patients with Cognitive Impairment Being Evaluated for Alzheimer's disease and Other Causes of Cognitive Impairment.
Frequently Asked Questions
What is the Projected CAGR value of the Alzheimer Drugs Market?
Alzheimer Drugs Market is expected to grow at a CAGR of 8% during the forecasting period 2022-2029.
Which region controlled the global market during 2022-2029?
North America region Controls the Alzheimer Drugs Market during 2022-2029.
Which is the fastest growing region in the Alzheimer Drugs Market?
Among all regions, Asia Pacific is the fastest growing market share during the forecast period.